Compare BridgeBio Pharma Inc (BBIO) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Walmart Stores Inc — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Walmart Stores Inc trades at $113.69 (market cap $904.83B). The key difference: Walmart Stores Inc is far larger — about 55× BridgeBio Pharma Inc's market cap, and Walmart Stores Inc pays a 0.87% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WMT | |
|---|---|---|
Market Cap | $16.46B | $904.83B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $134.20 |
52-Week Low | $44.81 | $95.05 |
Enterprise Value | $18.02B | $968.28B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Walmart (WMT) trades at $114.78, up 0.77% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong revenue growth to $681.0B in 2025 and a rising net income margin of 2.85%. Analyst consensus is strongly bullish with a $142.10 price target, though technical indicators show resistance near $115. Recent news highlights operational expansions in drone delivery and AI tools, alongside competitive pressures as Amazon overtakes it on the Fortune 500.
The outlook for WMT is positive based on fundamental strength and analyst optimism, but near-term technical resistance and competitive risks warrant caution. Investment opportunity lies in its consistent earnings performance and dividend yield, while risks include market volatility and execution challenges in e-commerce growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
